SARS-CoV-2 emerged in late 2019 and has since spread around the world, causing a pandemic of the respiratory disease COVID-19. Detecting antibodies against the virus is an essential tool for tracking infections and developing vaccines. Such tests, primarily utilizing the enzyme-linked immunosorbent assay (ELISA) principle, can be either qualitative (reporting positive/negative results) or quantitative (reporting a value representing the quantity of specific antibodies). Quantitation is vital for determining stability or decline of antibody titers in convalescence, efficacy of different vaccination regimens, and detection of asymptomatic infections. Quantitation typically requires two-step ELISA testing, in which samples are first screened in a qualitative assay and positive samples are subsequently analyzed as a dilution series. To overcome the throughput limitations of this approach, we developed a simpler and faster system that is highly automatable and achieves quantitation in a single-dilution screening format with sensitivity and specificity comparable to those of ELISA.
【저자키워드】 SARS-CoV-2, viral infection, Infectious-disease diagnostics, 【초록키워드】 COVID-19, Efficacy, vaccination, pandemic, Vaccines, antibody, Infection, virus, ELISA, asymptomatic infections, Spread, enzyme-linked immunosorbent assay, stability, Sensitivity and specificity, Respiratory disease, Antibody titer, convalescence, respiratory, Quantitative, Antibody titers, specific antibodies, enzyme, quantity, regimens, limitation, quantitation, dilution series, positive sample, ELISA testing, approach, enzyme-linked immunosorbent, analyzed, screened, faster, overcome, comparable, representing, 【제목키워드】 SARS-CoV-2 antibody, homogeneous,